Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Trevi Therapeutics, Inc. - Common Stock (NQ:TRVI)

10.99 +0.34 (+3.19%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Trevi Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Trevi Therapeutics Inc (NASDAQ:TRVI) Reports Q3 2025 Results, Narrows Loss and Outlines Phase 3 Plans ↗
Trevi Therapeutics reported a narrower-than-expected Q3 2025 loss. The biopharma firm is preparing its Phase 3 program for Haduvio and has cash into 2028. 
Via Chartmill
News headline image
Earnings Scheduled For November 13, 2025 ↗
 
Via Benzinga
News headline image
A Peek at Trevi Therapeutics's Future Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Earnings Preview For Trevi Therapeutics ↗
 
Via Benzinga
News headline image
Trevi Therapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Earnings Outlook For Trevi Therapeutics ↗
 
Via Benzinga
News headline image
This Adient Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Dow Gains Over 100 Points; US Job Openings Increase In April ↗
 
Via Benzinga
Topics Stocks
News headline image
Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients ↗
Trevi's Haduvio met its primary endpoint in a Phase 2b trial for IPF-related chronic cough, with statistically significant results at multiple doses. 
Via Benzinga
News headline image
Earnings Scheduled For March 18, 2025 ↗
 
Via Benzinga
News headline image
Unusual volume stocks are being observed in Tuesday's session. ↗
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps ↗
Trevi's Haduvio met the primary endpoint in a Phase 2a trial, showing a significant reduction in cough frequency with no serious adverse events reported. 
Via Benzinga
News headline image
Top movers in Monday's pre-market session ↗
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher ↗
 
Via Benzinga
Topics Stocks
News headline image
Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook ↗
 
Via Benzinga
News headline image
Nasdaq Down 50 Points; US Initial Jobless Claims Rise ↗
 
Via Benzinga
News headline image
Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday? ↗
Trevi Therapeutics' CORAL trial progresses unchanged after a positive SSRE review, with topline results for chronic cough in IPF expected by mid-2025. 
Via Benzinga
News headline image
TRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q2 2024 ↗
TRVI stock results show that Trevi Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
TRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q1 2024 ↗
TRVI stock results show that Trevi Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
TRVI Stock Earnings: Trevi Therapeutics Beats EPS for Q4 2023 ↗
TRVI stock results show that Trevi Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Earnings Scheduled For March 20, 2024 ↗
Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ:TIGR) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.